An Open-Label, Two-Stage, Dose-Escalation, Parallel Group Study to Evaluate the Safety and Pharmacokinetics Profile of Proellex (CDB-4124) in Female Patients With Impaired Hepatic Function and Healthy Adult Volunteers.

Trial Profile

An Open-Label, Two-Stage, Dose-Escalation, Parallel Group Study to Evaluate the Safety and Pharmacokinetics Profile of Proellex (CDB-4124) in Female Patients With Impaired Hepatic Function and Healthy Adult Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2014

At a glance

  • Drugs Telapristone (Primary)
  • Indications Uterine leiomyoma
  • Focus Pharmacokinetics
  • Sponsors Repros Therapeutics
  • Most Recent Events

    • 27 Aug 2014 Primary endpoint of safety profile has been removed as reported by ClinicalTrials.gov.
    • 17 Jul 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 17 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top